Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Bone marrow-derived mesenchymal stem cells + hyaluronic acid** is an investigational combination therapy consisting of autologous or allogeneic bone marrow-derived mesenchymal stem cells (BM-MSCs) and hyaluronic acid (HA), typically administered by intra-articular injection for the treatment of joint disorders such as osteoarthritis. **BM-MSCs** are multipotent stromal cells capable of modulating immune responses, exerting anti-inflammatory effects, stimulating tissue repair, and differentiating into chondrocytes, contributing to cartilage regeneration. **Hyaluronic acid** acts as a viscosupplement, providing lubrication, reducing inflammation, and supporting chondrogenesis by enhancing the viability and proliferation of BM-MSCs. The combination is under investigation in preclinical and clinical studies for its potential to synergistically improve outcomes in articular cartilage repair and osteoarthritis by leveraging both regenerative (cellular) and lubricating/structural (HA) mechanisms[1][2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bone marrow-derived mesenchymal stem cells + hyaluronic acid.